Literature DB >> 32144472

A bioengineered arginine-depleting enzyme as a long-lasting therapeutic agent against cancer.

Sai-Fung Chung1, Chi-Fai Kim1, Suet-Ying Tam1, Man-Chung Choi1, Pui-Kin So1, Kwok-Yin Wong2, Yun-Chung Leung3, Wai-Hung Lo4.   

Abstract

L-Arginine (L-Arg) depletion has attracted great attention in cancer therapy. Although two types of arginine-depleting enzymes, arginine deiminase (ADI) and human arginase I, are undergoing clinical trials, random site of PEGylation, low efficacy of heavy metal as co-factor, and immunogenicity limit the performance of these drugs and cause difficulty in a homogeneous production. Here we screened ten catalytic metal ions and have successfully produced a site-specific mono-PEGylated human arginase I mutant by conjugating the Cys45 residue to PEG-maleimide to minimize the decrease in activity and produce a homogeneous product. The catalytic efficiency trend of metal ion-enriched human arginase I mutant (HAI) was Co2+ > Ni2+ ≫ Mn2+. The overall kcat/KM values of Co-HAI and Ni-HAI were higher than Mn-HAI by ~ 8.7- and ~ 5.2-folds, respectively. Moreover, the results of enzyme kinetics and circular dichroism spectrometry demonstrated that the 20 or 40 kDa linear and branched PEG attached on the HAI surface did not affect the enzyme activity and the protein secondary structures. In vitro studies showed that both Co-HAI-PEG20L and Ni-HAI-PEG20L inhibited the growth of eight types of cancer cell lines. The pharmacodynamic study in mice demonstrated that the i.p. administration of Co-HAI-PEG20L at 13 mg/kg and Ni-HAI-PEG20L at 15 mg/kg was able to maintain a L-Arg level below its detection limit for over 120 h after one injection. The body weights of mice could return to normal levels within 5 days after injection, showing that the doses were well-tolerated. Therefore, both the Ni-HAI-PEG20L and Co-HAI-PEG20L are promising candidates for cancer therapy. KEY POINTS: • Mono-PEGylation applied on human arginase I mutant (HAI) successfully. • The catalytic efficiency of Co- and Ni-enriched HAI was higher than the wild type. • At least eight types of cancer cell lines were inhibited by Co- and Ni-HAI-PEG20L. • Co- and Ni-HAI-PEG20L were able to achieve weekly depletion of L-Arg. Graphical abstract.

Entities:  

Keywords:  Divalent metal ions; Human arginase I; L-Arg; Pharmacodynamics; Site-specific mono-PEGylation

Mesh:

Substances:

Year:  2020        PMID: 32144472     DOI: 10.1007/s00253-020-10484-4

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  34 in total

1.  Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts.

Authors:  Evan S Glazer; Everett M Stone; Cihui Zhu; Katherine L Massey; Amir N Hamir; Steven A Curley
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

2.  Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.

Authors:  G K Abou-Alfa; S Qin; B-Y Ryoo; S-N Lu; C-J Yen; Y-H Feng; H Y Lim; F Izzo; M Colombo; D Sarker; L Bolondi; G Vaccaro; W P Harris; Z Chen; R A Hubner; T Meyer; W Sun; J J Harding; E M Hollywood; J Ma; P J Wan; M Ly; J Bomalaski; A Johnston; C-C Lin; Y Chao; L-T Chen
Journal:  Ann Oncol       Date:  2018-06-01       Impact factor: 32.976

3.  Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion.

Authors:  Paul Ning-Man Cheng; Tin-Lun Lam; Wai-Man Lam; Sam-Mui Tsui; Anthony Wai-Ming Cheng; Wai-Hung Lo; Yun-Chung Leung
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

4.  Crystal structure of human arginase I at 1.29-A resolution and exploration of inhibition in the immune response.

Authors:  Luigi Di Costanzo; Guadalupe Sabio; Alfonso Mora; Paulo C Rodriguez; Augusto C Ochoa; Francisco Centeno; David W Christianson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-02       Impact factor: 11.205

5.  Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.

Authors:  Paolo A Ascierto; Stefania Scala; Giuseppe Castello; Antonio Daponte; Ester Simeone; Alessandro Ottaiano; Gerardo Beneduce; Vincenzo De Rosa; Francesco Izzo; Maria Teresa Melucci; C Mark Ensor; Archie W Prestayko; Frederick W Holtsberg; John S Bomalaski; Mike A Clark; Niramol Savaraj; Lynn G Feun; Theodore F Logan
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

6.  Rational surface engineering of an arginine deiminase (an antitumor enzyme) for increased PEGylation efficiency.

Authors:  Feng Cheng; Jianhua Yang; Ulrich Schwaneberg; Leilei Zhu
Journal:  Biotechnol Bioeng       Date:  2019-06-11       Impact factor: 4.530

7.  Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.

Authors:  Charles Mark Ensor; Frederick W Holtsberg; John S Bomalaski; Mike A Clark
Journal:  Cancer Res       Date:  2002-10-01       Impact factor: 12.701

8.  Optimization of PEGylation reaction time and molar ratio of rhG-CSF toward increasing bioactive potency of monoPEGylated protein.

Authors:  Jamila Behi; Rym Hassiki; Nadia Ben Said; Balkiss Bouhaouala-Zahar; Mohamed Lamine Benkhoud
Journal:  Int J Biol Macromol       Date:  2017-11-20       Impact factor: 6.953

Review 9.  Certolizumab pegol: in Crohn's disease.

Authors:  Stephanie K A Blick; Monique P Curran
Journal:  BioDrugs       Date:  2007       Impact factor: 5.807

10.  Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth.

Authors:  Shira L Cramer; Achinto Saha; Jinyun Liu; Surendar Tadi; Stefano Tiziani; Wupeng Yan; Kendra Triplett; Candice Lamb; Susan E Alters; Scott Rowlinson; Yan Jessie Zhang; Michael J Keating; Peng Huang; John DiGiovanni; George Georgiou; Everett Stone
Journal:  Nat Med       Date:  2016-11-21       Impact factor: 53.440

View more
  4 in total

1.  Functionalized quinolizinium-based fluorescent reagents for modification of cysteine-containing peptides and proteins.

Authors:  Karen Ka-Yan Kung; Cai-Fung Xu; Wa-Yi O; Qiong Yu; Sai-Fung Chung; Suet-Ying Tam; Yun-Chung Leung; Man-Kin Wong
Journal:  RSC Adv       Date:  2022-02-22       Impact factor: 3.361

2.  Mono-PEGylated thermostable Bacillus caldovelox arginase mutant (BCA-M-PEG20) induces apoptosis, autophagy, cell cycle arrest and growth inhibition in gastric cancer cells.

Authors:  Sai-Fung Chung; Suet-Ying Tam; Chi-Fai Kim; Hiu-Chi Chong; Leo Man-Yuen Lee; Yun-Chung Leung
Journal:  Invest New Drugs       Date:  2022-07-20       Impact factor: 3.651

3.  Mono-PEGylation of a Thermostable Arginine-Depleting Enzyme for the Treatment of Lung Cancer.

Authors:  Sai-Fung Chung; Chi-Fai Kim; Sui-Yi Kwok; Suet-Ying Tam; Yu Wai Chen; Hiu-Chi Chong; Siu-Lun Leung; Pui-Kin So; Kwok-Yin Wong; Yun-Chung Leung; Wai-Hung Lo
Journal:  Int J Mol Sci       Date:  2020-06-14       Impact factor: 5.923

4.  Recombinant Bacillus caldovelox Arginase Mutant (BCA-M) Induces Apoptosis, Autophagy, Cell Cycle Arrest and Growth Inhibition in Human Cervical Cancer Cells.

Authors:  Sai-Fung Chung; Chi-Fai Kim; Ho-Yin Chow; Hiu-Chi Chong; Suet-Ying Tam; Yun-Chung Leung; Wai-Hung Lo
Journal:  Int J Mol Sci       Date:  2020-10-09       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.